ClinicalTrials.gg
CompletedNCT04667949Updated Jan 13, 2026Results posted

Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients

A Phase 4 interventional study of Fingolimod 0.5mg in Relapsing Multiple Sclerosis (RMS), sponsored by Novartis Pharmaceuticals. Completed at 13 sites in China. Open to participants aged 10 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
98
Allocation
Not applicable
Ages
10 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.

Enrollment
24th of 34
98 · median 167
Started
2021
the only one that year
Phase 4
17 of 34
none open now
Registered
32nd of 34
by date
Lead sponsor
20 of 34
Novartis Pharmaceuticals

Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 24th largest by enrollment, is the only one that started in 2021, is one of 17 in phase 4, and was the 32nd registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 10 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing fingolimod in Multiple Sclerosis, or all of them as a file.
02

Study summary

The main purpose of this study was to assess the efficacy and safety of 0.5mg Fingolimod (Gilenya) in Chinese patients with relapsing multiple sclerosis (RMS)

Read the detailed description

This was a 24-month, open-label, multicenter, interventional, single-arm study to collect efficacy and, safety of oral fingolimod 0.5 mg/day in approximately 100 relapsing multiple sclerosis (RMS) participants in China.

The study consisted of three Phases:

  • Screening (up to 1 month): After signing informed consent, participants entered a Screening Phase to determine eligibility according to inclusion and exclusion criteria.
  • Treatment Period (24 months): On visit Day 1, all eligibility criteria were confirmed, including a pre-dose ECG and vital signs. The first dose of study drug was taken in the clinic on Day 1 and the participant was monitored for 6 hours after the first dose administration before discharge. Participants returned to site for evaluation at month 1 and then every three months until the end of treatment up to 24 months.
  • Follow Up (2 months): Subjects who completed Treatment Period or discontinued from treatment returned for the Follow-up visit 2 months after the last dose of study drug.
03

Conditions studied

  • Relapsing Multiple Sclerosis (RMS)

Browse trials for

Keywords

  • Relapsing Multiple Sclerosis (RMS)
  • Fingolimod
  • Adult
  • Pediatric
  • China
04

Who can participate

Ages eligible
10 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant 10 to 17 years old inclusive with weight > 40kg.
  • Participant 18 to 65 years old inclusive;
  • Participants with relapsing multiple sclerosis
  • Participants never used fingolimod before enrollment
  • Subjects with Expanded Disability Status Scale (EDSS) score of 0 - 6.0 (inclusive) at Screening

Exclusion criteria

Exclusion Criteria:

  • Participants with certain cardiovascular conditions and/or findings in the screening .
  • Diagnosis of macular edema during screening visit.
  • Increased risk for opportunistic infections
  • Participants with known active .
  • Participants who have been treated with teriflunomide within 3.5 months prior to baseline, except if active washout.
  • Participants with severe active infections, active chronic infection.
  • Participants with severe liver impairment.
  • Pregnant confirmed by a positive pregnancy test or nursing (lactating) women.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    Fingolimod

    Fingolimod 0.5 mg capsule taken orally once daily

    Drug: Fingolimod 0.5mg

Interventions

  • Subjects received fingolimod 0.5mg capsule QD up to month 24

    Also known as: FTY720

06

What researchers measure

Primary outcomes

  1. Adjusted Annualized Relapse Rate (ARR) in Adult Group

    A confirmed relapse is any relapse that is accompanied by an increase of at least 0.5 on the EDSS or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS) as confirmed by the treating physician. The adjusted annualized relapse rate (ARR) was estimated by a negative binomial regression model with log-link function, the cumulative number of confirmed MS relapses per subject as the response variable, number of relapses in the previous two years before enrollment and baseline EDSS as continuous covariates. Natural log of time on study in years was used as the offset variable to account for the varying lengths of subjects' time in the study. The adjusted ARR (i.e.model-based estimate adjusted for covariates) and the corresponding 95% confidence interval were obtained. As per SAP this analysis was only performed for the Adult group. Descriptive data is presented in subsequent OMs.

    Time frame: Baseline to Month 24

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (AE) and Serious Adverse Events (SAE)

    An adverse event (AE) is any untoward medical occurrence in a clinical investigation subject after providing written informed consent for participation in the study. For reporting purposes, the main focus was on treatment emergent adverse event (TEAE), defined as any AE which started on or after the day of first dose of study medication or events present prior to the start of treatment but increased in severity.

    Time frame: From first dose of study treatment to 45 days after last study dose up to aproximately 25.5 months

  2. Annualized Rate of the Number of New or Newly Enlarged T2 Lesions

    Obtained from fitting a negative binomial regression model with log-link function, the total number of new or newly enlarged T2 lesions during the treatment period (per participant) as the response variable. The model included baseline age and volume of T2 lesions at baseline as continuous covariates. Natural log of time from screening scan in years was used as the offset. Baseline is defined as the last non-missing assessment obtained prior to the first administration of study drug. As per SAP this analysis was only performed for the Adult group.

    Time frame: Baseline to end of treatment (up to Month 24)

  3. Change From Baseline in Number of New or Newly Enlarged T2 Lesions

    Number of new/newly enlarged T2 lesions since baseline as measured by MRI

    Time frame: Baseline up to Month 24

  4. Change From Baseline in T2 Lesion Volume

    T2 lesion volume as measured by MRI and calculated as post-baseline value - baseline value

    Time frame: Baseline up to Month 24

  5. Number of Gd-enhancing T1 Lesions Per Scan in Adult Group

    Obtained from fitting a negative binomial regression model with log-link function, the total number of Gd-enhancing T1 lesions during the treatment period (per patient) as the response variable. The model included baseline age and number of Gd-enhancing T1 lesions at baseline as continuous covariates. Natural log of the number of MRI scans was used as the offset. MRI scans were performed at baseline, month 12 and month 24 and End of treatment for participants that discontinued treatment. Unscheduled MRIs could be performed at the investigator's judgement. As per SAP this analysis was only performed for the Adult group.

    Time frame: Baseline up to Month 24

  6. Number of Gd-enhancing T1 Lesions

    Number of Gd-enhancing T1 lesions as measured by MRI

    Time frame: Baseline up to Month 24

  7. Change From Baseline in Gd-enhancing T1 Lesion Volume

    Gd-enhancing T1 lesion volume as measured by MRI and calculated as post-baseline value - baseline value

    Time frame: Baseline up to Month 24

  8. Number of T1 Hypo-intense Lesions

    Number of T1 hypo-intense lesions as measured by MRI

    Time frame: Baseline up to Month 24

  9. Change From Baseline in T1 Hypo-intense Lesion Volume

    T1 hypo-intense lesions as measured by MRI and calculated as post-baseline value - baseline value

    Time frame: Baseline up to Month 24

07

Results

Posted Aug 29, 2025

Participant flow

Participants were enrolled at 13 sites in China

Participant flow — Overall Study
MilestoneFingolimod (< 18 Years)Fingolimod > 18 Years
Started1187
Completed1075
Not completed112
Withdrew: Adverse event02
Withdrew: Lost to follow-up01
Withdrew: Physician decision02
Withdrew: Subject decision17

Outcome measures

Post-hocParticipant Based Annualized Relapse Rate (ARR)

A relapse is an appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event which is present for at least 24 hours in the absence of fever or infection. A relapse is confirmed by the treating physician when it is accompanied by an increase of at least 0.5 on the Expanded Disability Status Scale (EDSS) or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS). Participant-based ARR was calculated by taking the total number of relapses observed for a participant divided by the total number of days in study of that participant and multiplied by 365.25.

Time frame:
Baseline to Month 24
Reported as:
Mean · relapses per participant-year
Participant Based Annualized Relapse Rate (ARR)
relapses per participant-yearFingolimod (< 18 Years)Fingolimod > 18 Years
All relapses - Participant based0.1952 ± 0.503140.0969 ± 0.50002
Confirmed relapses - Participant based0.0460 ± 0.152530.0372 ± 0.24424
Post-hocTime Based Annualized Relapse Rate (ARR)

A relapse is an appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event which is present for at least 24 hours in the absence of fever or infection. A relapse is confirmed by the treating physician when it is accompanied by an increase of at least 0.5 on the Expanded Disability Status Scale (EDSS) or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS). Time-based ARR was calculated by taking the total number of relapses observed for all subjects within an age group divided by the total number of days in study of all subjects within the group and multiplied by 365.25 days.

Time frame:
Baseline to Month 24
Reported as:
Number · relapses per participant-year
Time Based Annualized Relapse Rate (ARR)
relapses per participant-yearFingolimod (< 18 Years)Fingolimod > 18 Years
All relapses - Time based0.1610.065
Confirmed relapses - Time based0.0540.019
PrimaryAdjusted Annualized Relapse Rate (ARR) in Adult Group

A confirmed relapse is any relapse that is accompanied by an increase of at least 0.5 on the EDSS or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS) as confirmed by the treating physician. The adjusted annualized relapse rate (ARR) was estimated by a negative binomial regression model with log-link function, the cumulative number of confirmed MS relapses per subject as the response variable, number of relapses in the previous two years before enrollment and baseline EDSS as continuous covariates. Natural log of time on study in years was used as the offset variable to account for the varying lengths of subjects' time in the study. The adjusted ARR (i.e.model-based estimate adjusted for covariates) and the corresponding 95% confidence interval were obtained. As per SAP this analysis was only performed for the Adult group. Descriptive data is presented in subsequent OMs.

Time frame:
Baseline to Month 24
Reported as:
Number · relapses per participant-year
Adjusted Annualized Relapse Rate (ARR) in Adult Group
relapses per participant-yearFingolimod > 18 Years
Adjusted Annualized Relapse Rate (ARR) in Adult Group0.018 (0.006 to 0.061)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (AE) and Serious Adverse Events (SAE)

An adverse event (AE) is any untoward medical occurrence in a clinical investigation subject after providing written informed consent for participation in the study. For reporting purposes, the main focus was on treatment emergent adverse event (TEAE), defined as any AE which started on or after the day of first dose of study medication or events present prior to the start of treatment but increased in severity.

Time frame:
From first dose of study treatment to 45 days after last study dose up to aproximately 25.5 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (AE) and Serious Adverse Events (SAE)
ParticipantsFingolimod (< 18 Years)Fingolimod > 18 Years
Adverse events (AEs)1186
Study treatment related AEs1081
Serious adverse events (SAEs)312
AEs leading to interruption of study treatment311
AEs leading to study discontinuation15
AEs leading to death00
SecondaryAnnualized Rate of the Number of New or Newly Enlarged T2 Lesions

Obtained from fitting a negative binomial regression model with log-link function, the total number of new or newly enlarged T2 lesions during the treatment period (per participant) as the response variable. The model included baseline age and volume of T2 lesions at baseline as continuous covariates. Natural log of time from screening scan in years was used as the offset. Baseline is defined as the last non-missing assessment obtained prior to the first administration of study drug. As per SAP this analysis was only performed for the Adult group.

Time frame:
Baseline to end of treatment (up to Month 24)
Reported as:
Number · Lesions per participant-year
Annualized Rate of the Number of New or Newly Enlarged T2 Lesions
Lesions per participant-yearFingolimod > 18 Years
Annualized Rate of the Number of New or Newly Enlarged T2 Lesions1.316 (0.762 to 2.272)
SecondaryChange From Baseline in Number of New or Newly Enlarged T2 Lesions

Number of new/newly enlarged T2 lesions since baseline as measured by MRI

Time frame:
Baseline up to Month 24
Reported as:
Mean · new / newly enlarged T2 lesions
Change From Baseline in Number of New or Newly Enlarged T2 Lesions
new / newly enlarged T2 lesionsFingolimod (< 18 Years)Fingolimod > 18 Years
12 months1.8 ± 1.931.8 ± 4.18
24 months2.1 ± 2.182.4 ± 4.84
SecondaryChange From Baseline in T2 Lesion Volume

T2 lesion volume as measured by MRI and calculated as post-baseline value - baseline value

Time frame:
Baseline up to Month 24
Reported as:
Median · milliliters
Change From Baseline in T2 Lesion Volume
millilitersFingolimod (< 18 Years)Fingolimod > 18 Years
12 months0.6140 (-17.607 to 34.748)0.3930 (-6.343 to 25.158)
24 months-1.6736 (-17.100 to 36.719)0.4065 (-5.741 to 26.322)
SecondaryNumber of Gd-enhancing T1 Lesions Per Scan in Adult Group

Obtained from fitting a negative binomial regression model with log-link function, the total number of Gd-enhancing T1 lesions during the treatment period (per patient) as the response variable. The model included baseline age and number of Gd-enhancing T1 lesions at baseline as continuous covariates. Natural log of the number of MRI scans was used as the offset. MRI scans were performed at baseline, month 12 and month 24 and End of treatment for participants that discontinued treatment. Unscheduled MRIs could be performed at the investigator's judgement. As per SAP this analysis was only performed for the Adult group.

Time frame:
Baseline up to Month 24
Reported as:
Number · Lesions per participant per scan
Number of Gd-enhancing T1 Lesions Per Scan in Adult Group
Lesions per participant per scanFingolimod > 18 Years
Number of Gd-enhancing T1 Lesions Per Scan in Adult Group0.376 (0.216 to 0.655)
SecondaryNumber of Gd-enhancing T1 Lesions

Number of Gd-enhancing T1 lesions as measured by MRI

Time frame:
Baseline up to Month 24
Reported as:
Mean · T1 lesions
Number of Gd-enhancing T1 Lesions
T1 lesionsFingolimod (< 18 Years)Fingolimod > 18 Years
12 months0.4 ± 0.700.4 ± 0.84
24 months0 ± 0.000.4 ± 1.83
SecondaryChange From Baseline in Gd-enhancing T1 Lesion Volume

Gd-enhancing T1 lesion volume as measured by MRI and calculated as post-baseline value - baseline value

Time frame:
Baseline up to Month 24
Reported as:
Median · microliters
Change From Baseline in Gd-enhancing T1 Lesion Volume
microlitersFingolimod (< 18 Years)Fingolimod > 18 Years
12 months-56.0 (-1392.5 to 418.0)0.00 (-1869.0 to 546.0)
24 months-56.0 (-632.7 to 0.0)0.00 (-1869.0 to 1082.0)
SecondaryNumber of T1 Hypo-intense Lesions

Number of T1 hypo-intense lesions as measured by MRI

Time frame:
Baseline up to Month 24
Reported as:
Mean · T1 hypo-intense lesions
Number of T1 Hypo-intense Lesions
T1 hypo-intense lesionsFingolimod (< 18 Years)Fingolimod > 18 Years
12 months14.6 ± 12.9717.0 ± 13.62
24 months13.4 ± 10.8616.7 ± 13.27
SecondaryChange From Baseline in T1 Hypo-intense Lesion Volume

T1 hypo-intense lesions as measured by MRI and calculated as post-baseline value - baseline value

Time frame:
Baseline up to Month 24
Reported as:
Median · microliters
Change From Baseline in T1 Hypo-intense Lesion Volume
microlitersFingolimod (< 18 Years)Fingolimod > 18 Years
12 months-77.500 (-6849.30 to 20341.80)44.000 (-4921.30 to 19035.00)
24 months-641.415 (-7444.50 to 1161.50)187.100 (-5772.20 to 19264.00)

Adverse events

Collected over Adverse events were reported from first dose of study treatment to 60 days after last study dose up to approximately 26 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Less Than 18 Years0/11 (0%)3/11 (27.3%)11/11 (100%)
Greater Than or Equal to 18 Years0/87 (0%)12/87 (13.8%)85/87 (97.7%)
Overall0/98 (0%)15/98 (15.3%)96/98 (98%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventLess Than 18 YearsGreater Than or Equal to 18 YearsOverall
SeizureNervous system disorders2/110/872/98
Febrile infectionInfections and infestations1/110/871/98
InfectionInfections and infestations1/110/871/98
PneumoniaInfections and infestations1/110/871/98
TonsillitisInfections and infestations1/110/871/98
Muscle twitchingMusculoskeletal and connective tissue disorders1/110/871/98
EpilepsyNervous system disorders1/110/871/98
SyncopeNervous system disorders1/110/871/98
Liver injuryHepatobiliary disorders0/113/873/98
Drug-induced liver injuryHepatobiliary disorders0/112/872/98
Most frequent other events
Showing 10 of 66
Most frequent other events
EventLess Than 18 YearsGreater Than or Equal to 18 YearsOverall
LymphopeniaBlood and lymphatic system disorders7/1124/8731/98
Lymphocyte count decreasedInvestigations2/1153/8755/98
LeukopeniaBlood and lymphatic system disorders5/1122/8727/98
Weight decreasedInvestigations5/118/8713/98
COVID-19Infections and infestations2/1135/8737/98
Alanine aminotransferase increasedInvestigations2/1133/8735/98
PyrexiaGeneral disorders and administration site conditions4/1112/8716/98
NasopharyngitisInfections and infestations4/119/8713/98
PharyngitisInfections and infestations4/110/874/98
Upper respiratory tract infectionInfections and infestations4/1121/8725/98

Baseline characteristics

Age, Continuous
Age, Continuous(years)Fingolimod (< 18 Years)Fingolimod > 18 YearsTotal
Mean12.8 ± 1.6032.3 ± 9.1130.1 ± 10.58
Sex: Female, Male
Sex: Female, Male(Participants)Fingolimod (< 18 Years)Fingolimod > 18 YearsTotal
Female35154
Male83644
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Fingolimod (< 18 Years)Fingolimod > 18 YearsTotal
American Indian or Alaska Native000
Asian118798
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Age categorical
Age categorical(Participants)Fingolimod (< 18 Years)Fingolimod > 18 YearsTotal
Children 2-11 years202
Adolescents 12-17 years909
Adults 18-64 years08787
Number of relapses in the last 12 months prior to screening
Number of relapses in the last 12 months prior to screening(relapses/year)Fingolimod (< 18 Years)Fingolimod > 18 YearsTotal
Mean1.7 ± 1.271.2 ± 0.471.3 ± 0.62
Number of relapses in 12 to 24 months prior to screening
Number of relapses in 12 to 24 months prior to screening(relapses/year)Fingolimod (< 18 Years)Fingolimod > 18 YearsTotal
Mean0.8 ± 1.250.7 ± 0.840.7 ± 0.89
08

Study locations

13 sites
  • Novartis Investigative Site
    Beijing, Beijing Municipality 100000, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510623, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510630, China
  • Novartis Investigative Site
    Zhengzhou, Henan 450052, China
  • Novartis Investigative Site
    Wuhan, Hubei 430030, China
  • Novartis Investigative Site
    Suzhou, Jiangsu 215004, China
  • Novartis Investigative Site
    Changchun, Jilin 130021, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Wenzhou, Zhejiang 325000, China
  • Novartis Investigative Site
    Beijing, 065001, China
  • Novartis Investigative Site
    Beijing, 100028, China
  • Novartis Investigative Site
    Guangzhou, 510260, China
  • Novartis Investigative Site
    Shanghai, 200040, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Mar 2025, 49 months.

Results were first posted in Aug 2025, 5 months after primary completion.

Of 36 industry-sponsored phase 4 interventional studies under Multiple Sclerosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 37. This study's 49 months is above that.

Counting every sponsor, half of 69 studies reached it within 34 months; a quarter within 23 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2020
First posted
Dec 16, 2020
StartActual
Feb 20, 2021
Primary completionActual
Mar 25, 2025
CompletionActual
Mar 25, 2025
Results first posted
Aug 29, 2025
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04667949
Responsible party
Sponsor
First posted
Dec 16, 2020
Start date
Feb 20, 2021
Primary completion
Mar 25, 2025
Completion
Mar 25, 2025
Results posted
Aug 29, 2025
Last update
Jan 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion